| WB | 咨询技术 | Rat |
| IF | 咨询技术 | Rat |
| IHC | 咨询技术 | Rat |
| ICC | 技术咨询 | Rat |
| FCM | 咨询技术 | Rat |
| Elisa | 咨询技术 | Rat |
| Aliases | GNRP; GRF1; CDC25; GRF55; CDC25L; H-GRF55; PP13187; ras-GRF1 |
| Entrez GeneID | 5923 |
| WB Predicted band size | Calculated MW: 145 kDa; Observed MW: 145 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Rat |
| Immunogen | A synthetic peptide of human CDC25 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CDC25抗体的参考文献示例(请注意，以下为示例性内容，实际引用时请核实文献的真实性)：
1. **文献名称**：*"Development of a monoclonal antibody specific for CDC25A and its application in breast cancer prognosis"*
**作者**：Smith J, et al.
**摘要**：该研究开发了一种针对CDC25A的高特异性单克隆抗体，并验证其在乳腺癌组织中的表达水平与患者预后不良的相关性，为靶向治疗提供潜在标志物。
2. **文献名称**：*"CDC25B phosphatase localization during cell cycle progression revealed by novel antibody staining"*
**作者**：Lee H, Chen X.
**摘要**：通过新型多克隆抗体技术，揭示了CDC25B在有丝分裂中的亚细胞定位动态变化，并探讨其在G2/M期调控中的关键作用。
3. **文献名称**：*"Targeting CDC25C with a neutralizing antibody suppresses DNA damage response in colorectal cancer cells"*
**作者**：Wang Y, et al.
**摘要**：研究利用中和性抗体抑制CDC25C活性，发现可阻断DNA损伤后的细胞周期检查点恢复，增强结直肠癌细胞对化疗的敏感性。
4. **文献名称**：*"Cross-reactivity analysis of commercial CDC25 antibodies: implications for experimental accuracy"*
**作者**：Gomez R, Patel S.
**摘要**：系统性评估了市售CDC25家族抗体的交叉反应性，强调选择高特异性抗体对减少实验误差的重要性，并提供了验证方案。
---
**注**：以上为模拟示例，实际文献需通过学术数据库(如PubMed、Web of Science)检索。建议使用关键词“CDC25 antibody validation”、“CDC25 phosphatase antibody application”进一步查找。
CDC25 antibodies are essential tools for studying the CDC25 phosphatase family, comprising CDC25A, CDC25B, and CDC25C. These dual-specificity phosphatases regulate cell cycle progression by dephosphorylating and activating cyclin-dependent kinases (CDKs) at specific checkpoints. CDC25A primarily governs G1/S transition, CDC25B initiates mitotic entry, and CDC25C activates the CDK1/cyclin B complex to trigger G2/M progression. Dysregulation of CDC25 isoforms is linked to uncontrolled proliferation, genomic instability, and cancer, making them potential therapeutic targets.
Antibodies against CDC25 proteins enable researchers to detect expression levels, subcellular localization, and post-translational modifications (e.g., phosphorylation) via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). They are critical for investigating CDC25 roles in DNA damage response, checkpoint recovery, and oncogenesis. For example, elevated CDC25B/C expression correlates with poor prognosis in cancers, while CDC25A degradation is tied to cell cycle arrest upon DNA damage.
Commercially available CDC25 antibodies vary in specificity; some target conserved regions across isoforms, while others distinguish individual members. Validation using knockout cell lines or siRNA is crucial to ensure reliability. These antibodies support both basic research and drug discovery, particularly in exploring CDC25 inhibitors as anticancer agents. Their applications extend to studying cell cycle deregulation in diseases beyond cancer, including neurodegenerative disorders and developmental defects.
×
